摘要
目的探讨依达拉奉治脑梗死患者的临床效果,关注患者治疗后血清中基质金属蛋白酶-3(MMP-3)和基质金属蛋白酶-9(MMP-9)的变化,以探讨其临床价值。方法选择在两院确诊的脑梗死患者,共116例,按入院顺序分为二组,对照组共58例,应用降颅压、减轻脑水肿、抗血小板制剂及脑细胞保护剂等为主的常规治疗,观察组共58例,在常规治疗基础上加用依达拉奉进地治疗。检测治疗后血清中MMP-3和MMP-9的表达差别。结果观察组患者治疗后的总有效率明显高于对照组。观察组患者治疗后血清中MMP-3和MMP-9的表达水平明显低于对照组。结论依达拉奉佐治脑梗死的临床疗效确切,且能有效降低血清中MMP-3和MMP-9的表达,有效阻断MMP-3和MMP-9介导的对疾病的促进作用,临床中可以积极应用。
Objective To investigate the effect and the expressions of MMP-3 and MMP-9 in patients with cerebral infarction by Edaravone treatment,for providing help to clinical work.Methods 116 cases with acute cerebral infarction were divided into two groups.The observation group（58 cases） was treated by routine and Edaravone treatment.The control group（58 cases） was only treated by routine treatment.The expressions of MMP-3 and MMP-9 were detected in post-treatment of Edaravone by ELISA methods.Results The total effect were higher in observation group than in the control group.The expressions of MMP-3 and MMP-9 were obviously lower in the observation group than in the control group after treatment.Conclusions The Edaravone can increase the effect in patients with cerebral infarction,decrease the expressions of MMP-3 and MMP-9,is worthy to be commened in clinical treatment.
出处
《中国医药指南》
2012年第2期40-41,共2页
Guide of China Medicine
